Quick Answer
CytomX Therapeutics, Inc. reported Stockholders Equity of $99.01 million for fiscal year 2025.
CytomX Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $99.01M | +21812.3% |
| 2024 | -$456.0K | +99.0% |
| 2023 | -$47.45M | +44.7% |
| 2022 | -$85.75M | -6.5% |
| 2022 | -$80.54M | -47.7% |
| 2022 | -$54.54M | -83.4% |
| 2022 | -$29.74M | -6379.1% |
| 2021 | -$459.0K | +94.1% |
| 2020 | -$7.77M | -115.2% |
| 2019 | $51.11M | -60.9% |
| 2018 | $130.88M | +87.3% |
| 2017 | $69.90M | -10.9% |
| 2016 | $78.48M | -37.7% |
| 2015 | $126.07M | +260.5% |
| 2014 | -$78.54M | -77.4% |
| 2013 | -$44.28M | -70.0% |
| 2012 | -$26.05M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $107.39M | +557.9% | -10.4% |
| June 30, 2025 | $119.91M | +484.0% | +378.7% |
| March 31, 2025 | $25.05M | +179.1% | +5593.2% |
| December 31, 2024 | -$456.0K | +99.0% | +98.1% |
| September 30, 2024 | -$23.45M | +54.2% | +24.9% |
| June 30, 2024 | -$31.23M | +63.3% | +1.4% |
| March 31, 2024 | -$31.68M | +63.4% | +33.2% |
| December 31, 2023 | -$47.45M | +44.7% | +7.4% |
- CytomX Therapeutics, Inc. showed an increase of +21812.3% in Stockholders Equity compared to the prior fiscal year.
- Over the 2012–2025 period, CytomX Therapeutics, Inc.’s stockholders equity has grown by 480.1% (from -$26.05 million to $99.01 million).
- The most recent figure is from CytomX Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 16, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: